YM begins Phase 2 brain metastases trial for nimotuzumab
May 27, 2010 by stephenkilmer · Leave a Comment
YM BioSciences (AMEX:YMI; TSX:YM) enrolled its first U.S. patient at the Florida Cancer Institute in a Phase 2 clinical trial evaluating its nimotuzumab drug in patients with brain metastases from NSCLC . Last year, the U.S. Department of the Treasury’s Office of Foreign Assets Control lifted the limitation on the development of nimotuzumab in the [...]
Listen to BioTuesdays 
